Market Intelligence, Clinical Progress, and High-Purity Reagents for Fibrosis and Oncology Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for EPRS/EPRS1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EPRS Recombinant Protein (Full-Length / ProRS Domain) High purity (>95%), Endotoxin controlled. Sequence Verified. Sf9/HEK293 expressed for native conformational folding. |
View EPRS Products |
| Gene Delivery | EPRS Promise-ORF / Lentivirus Particles Full-length human EPRS ORF for stable cell line construction and overexpression validation. |
View EPRS Products |
| Benchmark Ab | Anti-EPRS Recombinant Antibody High-affinity positive control for Western Blot, IHC, and immunoprecipitation assays. |
View EPRS Products |
| Validator | EPRS siRNA Set Target-specific gene knockdown validation to confirm target engagement and phenotypic rescue. |
View EPRS Products |
| Related Target A | COL1A1 (Collagen Type I Alpha 1) Downstream effector of EPRS; proline-rich collagen synthesis is directly regulated by EPRS activity. |
View COL1A1 Products |
| Related Target B | KARS (Lysyl-tRNA Synthetase) Component of the multi-tRNA synthetase complex (MSC); critical for selectivity and off-target safety screening. |
View KARS Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Activity & Selectivity Screening | High-purity (>95%) recombinant EPRS ProRS and GluRS domains with verified theoretical molecular weight and high stability. |
| Multi-Synthetase Complex (MSC) Off-Target Profiling | A complete panel of homolog proteins (KARS, IARS, LARS) strictly verified by mass spectrometry for counter-screening. |
| Lack of Validated Positive Controls | Sequence-verified clinical benchmark antibodies and high-titer lentiviral expression vectors included in the ecosystem. |
| RNA-Binding Interference (GAIT Complex) | Endotoxin-controlled, RNAse-free recombinant proteins suitable for nucleic acid interaction assays. |
Live EPRS R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Glutamyl-Prolyl-tRNA Synthetase (EPRS/EPRS1) is gaining significant momentum, primarily driven by its dual role in collagen translation (fibrosis) and translation control of oncogenic transcripts (cancer). While early-generation prolyl-tRNA synthetase (PRS) inhibitors like Halofuginone faced clinical limitations due to systemic toxicity, the next wave of drug discovery focuses on highly selective, tissue-targeted small molecule inhibitors and novel targeted protein degraders (PROTACs). Daewoong Pharmaceutical's DWN12088 (a selective PRS inhibitor) has paved the way in clinical trials for idiopathic pulmonary fibrosis (IPF), highlighting the transition from broad aminoacyl-tRNA synthetase inhibition to highly precise, indication-specific modulation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Daewoong Pharmaceutical, TyrPharma | Idiopathic Pulmonary Fibrosis (IPF), Solid Tumors | High-throughput tRNA aminoacylation assays (Requires high-purity, active recombinant ProRS domain). |
| PROTACs / Degraders | Arvinas, Academic Institutions | Breast Cancer, Inflammatory Diseases | Target engagement and ternary complex formation assays (Requires sequence-verified WT and mutant EPRS proteins). |
| Monoclonal Antibodies | Pre-clinical programs | Autoimmune Diseases, Fibrosis | Epitope mapping and cell-surface binding kinetics (Requires HEK293-expressed extracellular loop/domain proteins). |